Biotech Archives - Page 121 of 795

2 minute read

Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval

January 22, 12:59 PM

FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extended overall survival, and a breakthrough for FGFR alterations in metastatic UC.

AMAM

2 minute read

Why Is Fatty Liver Disease Focused Sagimet Biosciences Stock Shooting Higher Today?

By Vandana Singh

January 22, 11:27 AM

Sagimet Biosciences reports positive results from FASCINATE-2 Phase 2b trial. Denifanstat demonstrates significant improvements in NASH patients with fibrosis at week 52.

SGMT

1 minute read

Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?

By Vandana Singh

January 22, 10:41 AM

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.

CHRS

1 minute read

Why Is HIV Drug Giant Gilead Stock Falling Monday?

By Vandana Singh

January 22, 10:23 AM

Gilead's Phase 3 EVOKE-01 study on Trodelvy in metastatic non-small cell lung cancer didn't meet overall survival endpoint. Despite numerical OS improvement, further exploration is planned.

GILD

1 minute read

Envoy Medical Announces Three Additional Patents For Implantable Cochlear Systems

By Benzinga Newsdesk

January 22, 10:03 AM

Expanding Innovation Portfolio to Support Delivering Hearing to Patients in Innovative WaysWHITE BEAR LAKE, Minnesota, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a

COCH

3 minute read

AIM ImmunoTech Announces That The First Subject Is Enrolled In The Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca’s Imfinzi For The Treatment Of Late-Stage Pancreatic Cancer

By Benzinga Newsdesk

January 22, 9:55 AM

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the first subject has been enrolled at Erasmus Medical Center ("Erasmus MC") in a Phase 1b/2 clinical trial combining AIM's Ampligen®

AIM

3 minute read

Biodexa CEO Issues Shareholder Letter Highlighting Progress In 2023 And Expected Milestones In 2024; Says With The Pipeline Stronger Than It Has Ever Been, We Are Enthusiastic About The Potential For Our Company In 2024 And Beyond

By Benzinga Newsdesk

January 22, 9:45 AM

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023and Expected Milestones in 2024CARDIFF, United Kingdom, Jan. 22, 2024 (GLOBE NEWSWIRE) – Biodexa

BDRX

2 minute read

Intelligent Bio Solutions Inc. Announces That DGP Plc Has Selected The Revolutionary Portable Intelligent Fingerprinting Drug Screening System To Enable In-House Drug Testing

By Benzinga Newsdesk

January 22, 9:42 AM

Construction logistics, security, and support specialist selects Intelligent Fingerprinting Drug Screening System to simplify and speed up workplace drug testing for its 450 employees and contractors"By using fingerprint

INBS

2 minute read

Johnson & Johnson’s Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions

By Surbhi Jain

January 22, 9:35 AM

Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diverse company with reliable dividend, but impacted by talc lawsuit settlement and Kenvue split-off.

AMAM

3 minute read

Arcutis Biotherapeutics, Inc. Announces ZORYVE Topical Foam, 0.3%, For The Treatment Of Seborrheic Dermatitis Launches In The United States

By Benzinga Newsdesk

January 22, 9:17 AM

First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this weekEffective, safe, and very well-tolerated steroid-free foam provides rapid disease

ARQT